Incidence and treatment of bone metastases in urological tumors

02/2021

MUDr. Jana Katolická, Ph.D.

Onkologicko-chirurgické oddělení LF MU a FN u sv. Anny, Brno

SUMMARY

Metastatic bone disease is commonly seen with urogenital cancer types - notably those with prostate (85%) and kidney (40%). Bone-targeted agents - bisphosphonates and denosumab - are potent inhibitors of bone resorption for prevention of skeletal-related events in patients with solid tumors. In a phase III study, denosumab significantly delayed skeletal-related events compared with zoledronic acid in patients with metastatic castration resistant prostate cancer and renal cancer. In addition, denosumab showed superior effects on pain and health-related quality of life in these patients.

Key words

skeletal-related event, bisphosphonates, denosumab